0000950170-23-068370.txt : 20231205 0000950170-23-068370.hdr.sgml : 20231205 20231205185849 ACCESSION NUMBER: 0000950170-23-068370 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231201 FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maduck Sean CENTRAL INDEX KEY: 0001698310 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 231468062 MAIL ADDRESS: STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED STREET 2: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 ownership.xml 4 X0508 4 2023-12-01 0001088856 CORCEPT THERAPEUTICS INC CORT 0001698310 Maduck Sean C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK CA 94025 false true false false See Remarks true Common Stock 2023-12-01 4 M false 10009 2.61 A 83300 D Common Stock 2023-12-01 4 M false 14991 3.29 A 98291 D Common Stock 2023-12-01 4 S false 25000 25.5619 D 73291 D Common Stock 2023-12-01 4 A false 582 25.97 A 73873 D Common Stock 2023-12-01 4 A false 582 0.00 A 74455 D Common Stock 10000 I See Footnote Common Stock 10000 I See Footnote Stock option (right to buy) 2.61 2023-12-01 4 M false 10009 0.00 D 2024-08-07 Common Stock 10009 10000 D Stock option (right to buy) 3.29 2023-12-01 4 M false 14991 0.00 D 2025-02-18 Common Stock 14991 16986 D Includes 1,460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.47 to $25.785. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics 2012 Incentive Award Plan on December 1, 2023. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Fully exercisable. President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission. /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 2023-12-05